


# Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (Review)

Horvath T, Azman H, Kennedy GE, Rutherford GW



**THE COCHRANE  
COLLABORATION®**

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2012, Issue 4

<http://www.thecochranelibrary.com>



---

Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection (Review)  
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## TABLE OF CONTENTS

HEADER . . . . .	1
ABSTRACT . . . . .	1
PLAIN LANGUAGE SUMMARY . . . . .	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . .	3
BACKGROUND . . . . .	5
OBJECTIVES . . . . .	5
METHODS . . . . .	5
RESULTS . . . . .	7
Figure 1. . . . .	8
Figure 2. . . . .	10
Figure 3. . . . .	11
Figure 4. . . . .	12
Figure 5. . . . .	12
Figure 6. . . . .	12
Figure 7. . . . .	13
Figure 8. . . . .	13
Figure 9. . . . .	13
Figure 10. . . . .	14
Figure 11. . . . .	14
Figure 12. . . . .	14
Figure 13. . . . .	14
ADDITIONAL SUMMARY OF FINDINGS . . . . .	15
DISCUSSION . . . . .	18
AUTHORS' CONCLUSIONS . . . . .	18
ACKNOWLEDGEMENTS . . . . .	18
REFERENCES . . . . .	19
CHARACTERISTICS OF STUDIES . . . . .	21
DATA AND ANALYSES . . . . .	29
Analysis 1.1. Comparison 1 Mobile phone text messages vs. standard care, Outcome 1 Viral load suppression at 52 weeks. . . . .	30
Analysis 1.2. Comparison 1 Mobile phone text messages vs. standard care, Outcome 2 ART adherence at 48-52 weeks: Text messages vs. standard care (overall). . . . .	30
Analysis 1.3. Comparison 1 Mobile phone text messages vs. standard care, Outcome 3 ART adherence at 48-52 weeks: Weekly text messages vs. standard care (overall). . . . .	31
Analysis 1.4. Comparison 1 Mobile phone text messages vs. standard care, Outcome 4 ART adherence at 48-52 weeks: Short weekly messages vs. standard care. . . . .	31
Analysis 1.5. Comparison 1 Mobile phone text messages vs. standard care, Outcome 5 ART adherence at 48 weeks: Long weekly messages vs. standard care. . . . .	32
Analysis 1.6. Comparison 1 Mobile phone text messages vs. standard care, Outcome 6 ART adherence at 48 weeks: Daily messages vs. standard care (overall). . . . .	32
Analysis 1.7. Comparison 1 Mobile phone text messages vs. standard care, Outcome 7 ART adherence at 48 weeks: Short daily messages vs. standard care. . . . .	33
Analysis 1.8. Comparison 1 Mobile phone text messages vs. standard care, Outcome 8 ART adherence at 48 weeks: Long daily messages vs. standard care. . . . .	34
Analysis 2.1. Comparison 2 Mobile phone text messages (comparing different intervals and lengths), Outcome 1 ART adherence at 48 weeks: Short weekly messages vs. long weekly messages. . . . .	34
Analysis 2.2. Comparison 2 Mobile phone text messages (comparing different intervals and lengths), Outcome 2 ART adherence at 48 weeks: Weekly vs. daily messages (overall). . . . .	35
Analysis 2.3. Comparison 2 Mobile phone text messages (comparing different intervals and lengths), Outcome 3 ART adherence at 48 weeks: Short vs. long messages (overall). . . . .	35
ADDITIONAL TABLES . . . . .	35
APPENDICES . . . . .	36

WHAT'S NEW . . . . .	37
HISTORY . . . . .	37
CONTRIBUTIONS OF AUTHORS . . . . .	37
DECLARATIONS OF INTEREST . . . . .	37
SOURCES OF SUPPORT . . . . .	37
DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . .	38
NOTES . . . . .	38
INDEX TERMS . . . . .	38

[Intervention Review]

# Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection

Tara Horvath<sup>1</sup>, Hana Azman<sup>1</sup>, Gail E Kennedy<sup>1</sup>, George W Rutherford<sup>1</sup>

<sup>1</sup>Global Health Sciences, University of California, San Francisco, San Francisco, California, USA

Contact address: Tara Horvath, Global Health Sciences, University of California, San Francisco, 50 Beale Street, Suite 1200, San Francisco, California, 94105, USA. [thorvath@psg.ucsf.edu](mailto:thorvath@psg.ucsf.edu).

**Editorial group:** Cochrane HIV/AIDS Group.

**Publication status and date:** Edited (no change to conclusions), published in Issue 4, 2012.

**Review content assessed as up-to-date:** 8 February 2012.

**Citation:** Horvath T, Azman H, Kennedy GE, Rutherford GW. Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection. *Cochrane Database of Systematic Reviews* 2012, Issue 3. Art. No.: CD009756. DOI: 10.1002/14651858.CD009756.

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## ABSTRACT

### Background

More than 34 million people are presently living with HIV infection. Antiretroviral therapy (ART) can help these people to live longer, healthier lives, but adherence to ART can be difficult. Mobile phone text-messaging has the potential to help promote adherence in these patients.

### Objectives

To determine whether mobile phone text-messaging is efficacious in enhancing adherence to ART in patients with HIV infection.

### Search methods

Using the Cochrane Collaboration's validated search strategies for identifying randomised controlled trials and reports of HIV interventions, along with appropriate keywords and MeSH terms, we searched a range of electronic databases, including the Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS), MEDLINE (via PubMed), PsycINFO, Web of Science, and the World Health Organization (WHO) Global Index Medicus. The date range was from 01 January 1980 to 01 November 2011. There were no limits to language or publication status.

### Selection criteria

Randomised controlled trials (RCTs) in which patients or their caregivers (in the case of infants and children) of any age, in any setting, and receiving ART were provided with mobile phone text messages as a means of promoting adherence to ART.

### Data collection and analysis

Two authors independently examined the abstracts of all identified trials. We initially identified 243 references. Seventeen full-text articles were closely reviewed. Both authors abstracted data independently, using a pre-designed, standardised data collection form. When appropriate, data were combined in meta-analysis.

## Main results

Two RCTs from Kenya were included in the review. One trial compared short weekly text messages against standard care. The other trial compared short daily, long daily, short weekly and long weekly messages against standard care. Both trials were with adult patients. In the trial comparing only short weekly messages to standard care, text messaging was associated with a lower risk of non-adherence at 12 months (RR 0.77, 95% CI 0.63 to 0.93) and with the non-occurrence of virologic failure at 12 months (RR 0.83, 95% CI 0.69 to 0.99).

In the trial that compared different intervals and lengths for text-messaging to standard care, long weekly text-messaging was not significantly associated with a lower risk of non-adherence compared to standard care (RR 0.79, 95% CI 0.60 to 1.04). Patients receiving weekly text-messages of any length were at lower risk of non-adherence at 48 weeks than were patients receiving daily messages of any length (RR 0.79, 95% CI 0.64 to 0.99). There were no significant differences between weekly text-messaging of any length (RR 1.01, 95% CI 0.75 to 1.37) and between short or long messaging at either interval (RR 0.99, 95% CI 0.78 to 1.27). Compared to standard care, any daily text-messaging, whether short or long, did not reduce the risk for non-adherence (RR 0.99, 95% CI 0.82 to 1.20).

In meta-analysis of both trials, any weekly text-messaging (i.e. whether short or long messages) was associated with a lower risk of non-adherence at 48-52 weeks (RR 0.78, 95% CI 0.68 to 0.89). The effect of short weekly text-messaging was also significant (RR 0.77, 95% CI 0.67 to 0.89).

## Authors' conclusions

There is high-quality evidence from the two RCTs that mobile phone text-messaging at weekly intervals is efficacious in enhancing adherence to ART, compared to standard care. There is high quality evidence from one trial that weekly mobile phone text-messaging is efficacious in improving HIV viral load suppression. Policy-makers should consider funding programs proposing to provide weekly mobile phone text-messaging as a means for promoting adherence to antiretroviral therapy. Clinics and hospitals should consider implementing such programs. There is a need for large RCTs of this intervention in adolescent populations, as well as in high-income countries.

## PLAIN LANGUAGE SUMMARY

### Mobile phone text messaging to help patients with HIV infection take their antiretroviral medications every day

More than 34 million people are presently living with HIV infection. Antiretroviral therapy (ART) can help these people to live longer, healthier lives, but because of side-effects, adherence (taking these medications every day) can be difficult. Mobile phone text-messaging has the potential to help promote adherence in these patients.

Two randomised controlled trials from Kenya were included in the review. One trial compared short weekly text messages against standard care. The other trial compared short daily, long daily, short weekly and long weekly messages against standard care.

In the trial comparing only short weekly messages to standard care, text messaging was associated with lower risk of non-adherence at 12 months, and with the non-occurrence of virologic failure at 12 months.

Combining the data from both trials, weekly mobile phone text-messaging was associated with greater ART adherence at 48-52 weeks. The effect of short weekly text-messaging was also significant.

In the trial that compared different intervals and lengths for text-messaging to standard care, long weekly text-messaging was not significantly associated with a lower risk of non-adherence compared to standard care. Patients receiving weekly text-messages of any length were at lower risk of non-adherence at 48 weeks than were patients receiving daily messages of any length. There were no significant differences between weekly text-messaging of any length and between short or long messaging at either interval. Compared to standard care, any daily text-messaging, whether short or long, did not reduce the risk for non-adherence.

## SUMMARY OF FINDINGS FOR THE MAIN COMPARISON *[Explanation]*

Mobile phone text messages compared to standard care for promoting adherence to antiretroviral therapy in patients with HIV infection						
Patient or population: Patients with HIV infection, on ART Settings: Kenya Intervention: Mobile phone text messages Comparison: standard care						
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	standard care	Mobile phone text messages				
Viral load suppression at 52 weeks	483 per 1000	401 per 1000 (333 to 478)	RR 0.83 (0.69 to 0.99)	538 (1 study)	⊕⊕⊕⊕ high	
ART adherence at 48-52 weeks: Text messages vs. standard care (overall)	465 per 1000	382 per 1000 (335 to 437)	RR 0.82 (0.72 to 0.94)	966 (2 studies)	⊕⊕⊕⊕ high	
ART adherence at 48-52 weeks: Weekly text messages vs. standard care (overall)	465 per 1000	363 per 1000 (316 to 414)	RR 0.78 (0.68 to 0.89)	898 (2 studies)	⊕⊕⊕⊕ high	
ART adherence at 48-52 weeks: Short weekly messages vs. standard care	465 per 1000	358 per 1000 (307 to 419)	RR 0.77 (0.66 to 0.9)	750 (2 studies)	⊕⊕⊕⊕ high	

ART adherence at 48 weeks: Long weekly messages vs. standard care	403 per 1000	318 per 1000 (242 to 419)	RR 0.79 (0.6 to 1.04)	213 (1 study)	⊕⊕○○ <b>low</b> <sup>1</sup>
ART adherence at 48 weeks: Short daily messages vs. standard care	403 per 1000	403 per 1000 (318 to 512)	RR 1 (0.79 to 1.27)	209 (1 study)	⊕⊕○○ <b>low</b> <sup>1</sup>
ART adherence at 48 weeks: Long daily messages vs. standard care	403 per 1000	395 per 1000 (310 to 500)	RR 0.98 (0.77 to 1.24)	211 (1 study)	⊕⊕○○ <b>low</b> <sup>1</sup>

\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

<sup>1</sup> Very few events.

## BACKGROUND

More than 34 million people were living with human immunodeficiency virus (HIV) infection in 2010 (UNAIDS 2011). Over 15 million of these people are clinically eligible for antiretroviral therapy (ART), but only around 5.2 million were receiving treatment (UNAIDS 2011). ART can lead to marked reductions in mortality at the population level (Palella 1998), but because of costs, lack of infrastructure and other issues, ART has become available in many low- and middle-income countries (LMIC) only in the past few years (WHO 2010). As provision of ART has become more widely available in LMIC with a high burden of HIV disease, mortality has begun to decline, but is still unacceptably high (WHO 2009).

ART can help patients to feel better, live longer and slow progression of the disease (UNAIDS 2011), but many patients find it difficult to comply with the regimens they have been prescribed (Mills 2006). Adherence to ART is crucial not only for the patient's survival but also to prevent drug resistance with resultant treatment failure and need to switch to a second-line regimen. In LMIC, second-line regimens are much more expensive than first-line regimens (WHO 2010). Another benefit of adherence is that patients with a suppressed HIV viral load are significantly less likely to transmit the infection to sexual partners (Anglemeyer 2011).

For these reasons, it is thus important to find better ways to help patients stay adherent to their ART regimens. As wireless telecommunications networks have spread rapidly throughout sub-Saharan Africa, South Asia, and other resource-limited settings with high HIV prevalence, sending text-messages on wireless mobile telephones has become an extremely popular means of communication among people in all sectors of society (Guardian 2009; iTWire 2011). Mobile phone text-messaging, also called short messaging service (SMS), has been proposed as an approach to enhancing patient adherence to ART regimens.

## OBJECTIVES

To review the evidence for the use of mobile phone text-messaging to enhance adherence to ART in patients with HIV infection.

## METHODS

### Criteria for considering studies for this review

#### Types of studies

Randomised controlled trials (RCT).

#### Types of participants

Adults or children on ART, in any setting.

#### Types of interventions

Interventions in which mobile phone text messages are used to promote adherence to ART delivered to a patient on ART or, in the case of an infant or child, to a caregiver. Text messaging must not have been bundled with other interventions unless the text messaging outcome data could be analyzed separately. Studies in which mobile phone voice speaking or voice messaging was the intervention were excluded. Studies in which the use of a "beeper" or "pager" was the intervention were excluded. The intervention must have been compared to standard interventions for promoting adherence or to a control condition that would not introduce confounding variables (i.e., not compared to another experimental intervention).

#### Types of outcome measures

##### Primary outcomes:

- Adherence
- Viral load suppression, as measured by the investigators

##### Secondary outcomes

- Quality of life (specifically measured as improvement in mental/emotional state)

#### Search methods for identification of studies

We used the Cochrane HIV/AIDS Group's validated search methods. We formulated a comprehensive and exhaustive search strategy in an attempt to identify all relevant studies regardless of language or publication status (published, unpublished, in press and in progress).

#### Electronic searches

##### Journal and trials databases

We searched the following electronic databases, in the period from 01 January 1980 to 01 November 2011:

- Cochrane Central Register of Controlled Trials (CENTRAL)
- EMBASE
- Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS)
- MEDLINE (via PubMed)
- PsycINFO
- Web of Science
- World Health Organization (WHO) Global Index Medicus

Along with MeSH terms and relevant keywords, we used the Cochrane Highly Sensitive Search Strategy for identifying reports

of randomised controlled trials in MEDLINE (Higgins 2008), and the Cochrane HIV/AIDS Group's existing strategies for identifying references relevant to HIV/AIDS. The search strategy was iterative, in that references of included studies were searched for additional references. All languages were included. See Appendix 1 for the example of our PubMed search strategy, which was modified as needed for use in the other databases.

Using a variety of relevant terms, we also searched the clinical trials registry at the WHO International Clinical Trials Registry Platform, which includes trials from many countries including all trials listed in "ClinicalTrials.gov." Four ongoing RCTs were identified (see "Ongoing studies," in the references). The searches were performed without limits to language or setting and were limited to human studies published from 1980 to the present.

#### Conference abstracts

We searched the online abstract archives of relevant conference proceedings, including the Conference on Retroviruses and Opportunistic Infections (CROI), the International AIDS Conference (IAC), and the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS). These conferences were searched from their inception dates (1993, 1985, and 2001 respectively) to the most recent conference (2011, 2010 and 2011, respectively).

#### Searching other resources

##### Handsearching of journals

Because the field of HIV/AIDS research is relatively new ( $\geq 1981$ ), virtually all scientific research relevant to HIV/AIDS is available in electronic journals or is accessible through online databases. (The same is true of research relevant to mobile phones.) For this reason we did not undertake handsearching of print copies of journals.

##### Contacting researchers in the field

We contacted individual researchers working in the field in an attempt to learn of any research we had not identified.

#### Data collection and analysis

Our methodology for data collection and analysis was based on the guidance of the Cochrane Handbook of Systematic Reviews of Interventions (Higgins 2008). Two authors (TH and HA), working independently, reviewed the abstracts of all studies identified through database searches or by other means. Where there was any question of eligibility, we obtained the full text of the article for closer examination.

#### Selection of studies

Search results were imported into a bibliographic citation management software (EndNote X4). Duplicate references were then

excluded. Reviewing only article titles, one author (TH) excluded all references that were clearly irrelevant. Two authors (TH and HA), working independently, then reviewed the titles, abstracts and descriptor terms of the remaining citations to identify potentially eligible reports. We obtained full text articles for all references identified as potentially meeting inclusion criteria. TH and HA reviewed these full text articles and applied the inclusion criteria to establish each study's eligibility or ineligibility. Studies were reviewed for relevance based on study design, intervention given, types of participants and outcome measures. Our plan was to resolve any differences of opinion through discussion, with a neutral third party arbiter standing by, but we had no disagreements.

#### Data extraction and management

After identifying trials for inclusion, two authors (TH and HA) working independently examined and extracted data from each study. TH and HA separately entered these data into standardised data extraction forms. Extracted data in the forms were then compared. There were no disagreements. Extracted information included:

- Study details: Complete citation, start and end dates, location, study design characteristics and other relevant details.
- Participant details: Number of participants, age range, gender, baseline viral load, other baseline characteristics, qualitative data in regard to quality of life, details of attrition.
- Intervention details: Mobile phone type, content of text messaging, frequency of text messaging, period of intervention, comparator.
- Outcome details: Outcomes measured, methodologies for measuring adherence and viral load count, outcome data.
- Bias assessment data: Details necessary to perform a bias risk assessment using the Cochrane tool described above.

#### Assessment of risk of bias in included studies

We used the Cochrane Collaboration tool (Higgins 2008) for assessing the risk of bias for each individual study, and present results in summary tables. For randomised trials, the Cochrane tool assesses risk of bias in individual studies across six domains: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting and other potential biases.

#### Quality of evidence

In addition to a risk of bias assessment using the Cochrane tool, we graded the quality of evidence of the literature using the Grades of Recommendation Assessment, Development and Evaluation (GRADE) approach (Guyatt 2008). We used the GRADEpro software, version 3.2, to perform our analyses (GRADEpro 2008). GRADE ranks the quality of evidence on four levels: "high," "moderate," "low" and "very low." Evidence from randomised controlled trials starts at "high," but can be downgraded based

on study limitations, inconsistency of results, indirectness of evidence, imprecision or for reporting bias. Evidence from observational studies starts at "low," but can be upgraded if the magnitude of treatment effect is very large, if there is a significant dose-response relation, or if all possible confounders would decrease the magnitude of an apparent treatment effect (Guyatt 2008). Evidence from observational studies can also be downgraded.

### Measures of treatment effect

We used Review Manager 5 (RevMan 2011) provided by the Cochrane Collaboration for preparing the review and for statistical analysis. We summarised dichotomous outcomes for effect using risk ratios (RR), with 95% confidence intervals (CI).

We calculated summary statistics using meta-analytic methods and present findings in regard to evidence quality in GRADE summary of findings tables, for all outcomes of interest.

### Unit of analysis issues

The unit of analysis was the individual patient on ART.

### Dealing with missing data

In our analyses of Pop-Eleches 2011, the number of events per arm was back-calculated from proportional figures provided by the authors. See these proportional figures in Characteristics of included studies.

### Assessment of heterogeneity

We examined heterogeneity between the trials using the  $I^2$  statistic. We would have interpreted an  $I^2$  estimate greater than 50% as indicating moderate or high levels of heterogeneity.

### Assessment of reporting biases

We minimised the potential for publication bias by using comprehensive search strategies, which included searching scientific literature from a wide range of databases, published or unpublished, written in any language. We also used funnel plots to assess the possibility of publication bias and did not find any.

### Data synthesis

When study populations, interventions, comparators and outcomes were sufficiently similar, we pooled the data across studies and estimated summary effect sizes using a fixed effect model. There was little heterogeneity between the trials. We summarised the quality of evidence provided by the two trials using GRADE summary of findings tables (Summary of findings for the main comparison, Summary of findings 2).

### Subgroup analysis and investigation of heterogeneity

We did not do subgroup analyses.

## RESULTS


### Description of studies

See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of studies awaiting classification; Characteristics of ongoing studies.

### Results of the search

Searches were conducted on 1 November, 2011, and produced 210 titles after 35 duplicates were removed. After initial screening and exclusion of 67 titles by one author (TH), 143 titles and abstracts were reviewed more closely by two authors (TH and HA). Applying the inclusion criteria relevant to study design, participant characteristics, intervention characteristics and outcome characteristics, each author independently examined the titles, abstracts, and descriptor terms of all references. The full-text article was obtained for all references identified as potentially meeting inclusion criteria. All other references were excluded. The two authors compared the results of their screening, and found agreement. See Figure 1 for a flowchart depicting our screening process.

Figure 1. Study flow diagram.



Seventeen full-text articles were examined closely by TH and HA. We identified two RCTs meeting our inclusion criteria for data extraction and possible meta-analysis (Lester 2010, Pop-Eleches 2011). Also, one article was identified as providing additional qualitative data for Pop-Eleches 2011 (Haberer 2010). In addition, we identified 4 ongoing studies (see Characteristics of ongoing studies below).

### Included studies

The two included studies were conducted in Kenya (Lester 2010, Pop-Eleches 2011). Both trials compared text-messaging to a control condition. In Lester 2010, the control condition was standard care. In Pop-Eleches 2011, the control condition was provision of a cell phone, but this cell phone received no study-related text messages or other communication.

**Lester 2010:** Lester and colleagues in Kenya randomly assigned 273 patients initiating ART to mobile phone text-messaging, and 265 to standard care. Text messages were brief ("Mambo", the Kiswahili term for "How are you?"), sent once weekly, with a response requested within 48 hours. The primary outcomes were self-reported ART adherence (measured as >95% of prescribed doses in the past 30 days, assessed at 6 months and 12 months) and suppression of plasma HIV viral load (<400 copies per  $\mu$ L) at 12 months. The analysis was by intention to treat.

Patients receiving text messages were at lower risk of reporting non-adherence to ART at 12 months (RR 0.77, 95% CI 0.63 to 0.93). Patients receiving text messages were also at lower risk of experiencing virologic failure (RR 0.83, 95% CI 0.69 to 0.99).

**Pop-Eleches 2011:** Pop-Eleches and colleagues in Kenya randomly assigned 431 patients recently initiating ART (<3 months) to one of four intervention conditions (receiving short or long mobile phone text messages, either daily or weekly) or to standard care (with provision of a mobile phone but no study-related communication). The messages were provided in English, Dhoulou or Kiswahili (as appropriate). The content of the short message was "This is your reminder." The content of the long message was "This is your reminder. Be strong and courageous. We care about you."

The primary outcome was ART adherence of <90% during each 12-week period of analysis, for 48 weeks. The analysis was by intention to treat. Adherence was also measured with a medication event monitoring system (MEMS).

- At 48 weeks, patients in any of the four intervention groups were at no lower risk of non-adherence than those in the control group (RR 0.89, 95% CI 0.74 to 1.06).
- Patients in either of the weekly message intervention groups (whether short message or long message) were at lower risk of non-adherence than those in the control group (RR 0.79, 95% CI 0.63 to 0.98).

- Patients receiving short weekly messages were not at significantly lower risk of non-adherence than were those in the control group (RR 0.78, 95% CI 0.59 to 1.03).

- Patients receiving long weekly messages were not at significantly lower risk of non-adherence than were those in the control group (RR 0.79, 95% CI 0.60 to 1.04).

- There was no difference in the risk for non-adherence in patients receiving short daily messages compared to those in the control group (RR 1.00, 95% CI 0.79 to 1.27).

- There was no difference in the risk for non-adherence in patients receiving long daily messages compared to those in the control group (RR 0.98, 95% CI 0.77 to 1.24).

- There was no difference in the risk for non-adherence in patients receiving any daily messages compared to those in the control group (RR 0.99, 95% CI 0.82 to 1.20).

- There was no difference in the risk for non-adherence in patients receiving weekly text messages of any length (RR 1.01, 95% CI 0.75 to 1.37), nor between short or long messaging at either interval (RR 0.99, 95% CI 0.78 to 1.27).

- Patients receiving weekly text messages of any length were at lower risk for non-adherence than were patients receiving daily messages of any length (RR 0.79, 95% CI 0.64 to 0.99).

### Excluded studies


We obtained the full text of 17 articles and later excluded 15 articles, representing 10 individual studies and two systematic reviews. One article was excluded because it was a protocol for an ongoing RCT and is more properly classified as an "Ongoing study," rather than an "Excluded study." Six articles were excluded because sending text messages was not the intervention (Simoni 2007, Skinner 2007, Reynolds 2008, Wang 2008, De Costa 2010, Kalichman 2011). Three articles were excluded because the studies were not randomised controlled trials (Puccio 2006, Ammassari 2011, Dowshen 2011). Two articles were excluded because they were letters in regard to studies that are included in this review (Chi 2010, Kelly 2011). Two articles were excluded because although they were systematic reviews, they did not include any RCTs meeting our inclusion criteria (Mukund Bahadur 2010, Saberi 2011). One article was excluded because participants in the control group were given the use of another experimental intervention (a "beeper") as the control condition (Hardy 2011). See Figure 1 for a flow diagram depicting our screening process.

One article (Haberer 2010) is counted as "excluded," but it does provide qualitative data about one of the trials included in this review (Pop-Eleches 2011). See below, under "Qualitative findings."

### Risk of bias in included studies

We used the Cochrane Collaboration's tool for assessing the risk of bias in each individual study (Higgins 2008). Overall, the risk of bias in these two trials is low. There was no blinding of participants. Study personnel and outcome assessors were blinded in Lester 2010, but it is not clear that they were blinded in Pop-Eleches 2011. Lack of blinding participants is unlikely to have affected study outcomes. In Pop-Eleches 2011, there is an unclear risk of bias due to a lack of clarity in regard to the allocation concealment method. See tables for Risk of bias in included studies, below, describing our assessment of bias risk in each trial, and see Figure 2 and Figure 3 for graphic representations of our assessment.

**Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.**



**Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.**

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Lester 2010	+	+	+	+	+	+	+
Pop-Eleches 2011	+	?	+	+	+	?	+

### Effects of interventions

See: [Summary of findings for the main comparison](#) Mobile phone text messages compared to standard care for promoting adherence to antiretroviral therapy in patients with HIV infection; [Summary of findings 2](#) Mobile phone text messages (comparing different intervals and lengths) for promoting adherence to antiretroviral therapy in patients with HIV infection

In both included trials, any mobile phone text-messaging (i.e. daily messages or weekly messages) was associated with ART adherence at 48-52 weeks (RR 0.82, 95% CI 0.72 to 0.94). Any weekly text-messaging (i.e. whether short or long messages) was associated

with ART adherence at 48-52 weeks (RR 0.78, 95% CI 0.68 to 0.89). Short weekly text-messaging was also associated with ART adherence at 48-52 weeks (RR 0.77, 95% CI 0.67 to 0.89). Using data only from [Lester 2010](#), short weekly text messaging was associated with the viral load suppression at 52 weeks (RR 0.83, 95% CI 0.69 to 0.99).

Neither trial addressed quality of life outcomes.

- See [Table 1](#), Effects of the interventions.

### Meta-analysis

As there was little heterogeneity between the two trials ( $\leq 19\%$ ), we used a fixed-effects model in our meta-analysis. In meta-analysis


of two trials, any mobile phone text-messaging (i.e., whether daily or weekly messages) was associated with greater ART adherence at 48-52 weeks (RR 0.82, 95% CI 0.72 to 0.94). The effect of any weekly text-messaging was also significant (RR 0.78, 95% CI 0.68 to 0.89), as was that of short weekly text-messaging (RR 0.77, 95% CI 0.67 to 0.89).

Because daily text-messaging in Pop-Eleches 2011 suggested no effect (RR 0.99, 95% CI 0.82 to 1.20, Analysis 1.6), the measured outcomes for "any text-messaging" may better indicate the efficacy


of either weekly mode of text-messaging, especially given the larger sample generated by pooling data from Lester 2010 with both weekly-message arms of Pop-Eleches 2011 (Analysis 1.3).

See Analysis 1.1; Analysis 1.2; Analysis 1.3; Analysis 1.4; Analysis 1.5; Analysis 1.6; Analysis 1.7; Analysis 1.8; Analysis 2.1; Analysis 2.2; and Analysis 2.3. See forest plots for each comparison in Figure 4, Figure 5, Figure 6, Figure 7, Figure 8, Figure 9, Figure 10, Figure 11, Figure 12, and Figure 13.


**Figure 4. Forest plot of comparison: I Mobile phone text messages vs. standard care, outcome: I.1 Viral load suppression at 52 weeks.**




**Figure 5. Forest plot of comparison: I Mobile phone text messages vs. control, outcome: I.1 ART adherence at 48-52 weeks: Text messages vs. standard care (overall).**




**Figure 6. Forest plot of comparison: I Mobile phone text messages vs. standard care, outcome: I.3 ART adherence at 48-52 weeks: Weekly text messages vs. standard care (overall).**




**Figure 7. Forest plot of comparison: I Mobile phone text messages vs. standard care, outcome: 1.4 ART adherence at 48-52 weeks: Short weekly messages vs. standard care.**



**Figure 8. Forest plot of comparison: I Mobile phone text messages vs. standard care, outcome: 1.5 ART adherence at 48 weeks: Long weekly messages vs. standard care.**




**Figure 9. Forest plot of comparison: I Mobile phone text messages vs. standard care, outcome: 1.7 ART adherence at 48 weeks: Short daily messages vs. standard care.**




**Figure 10. Forest plot of comparison: 1 Mobile phone text messages vs. standard care, outcome: 1.8 ART adherence at 48 weeks: Long daily messages vs. standard care.**




**Figure 11. Forest plot of comparison: 2 Mobile phone text messages (intervals and durations), outcome: 2.1 ART adherence at 48 weeks: Short weekly messages vs. long weekly messages.**



**Figure 12. Forest plot of comparison: 2 Mobile phone text messages (intervals and durations), outcome: 2.2 ART adherence at 48 weeks: Weekly vs. daily messages (overall).**



**Figure 13. Forest plot of comparison: 2 Mobile phone text messages (intervals and durations), outcome: 2.3 ART adherence at 48 weeks: Short vs. long messages (overall).**



**Qualitative findings**

[Haberer 2010](#) provides qualitative data for [Pop-Eleches 2011](#), although they do not measure the quality of life outcomes specified in this review's protocol. Instead, Haberer and colleagues discuss feasibility issues in implementing the intervention of Pop-Eleches and colleagues. Based on qualitative interviews with participants, the most important issues pointed out by Haberer and colleagues were the need for detailed, multi-session trainings for patients in the use of mobile phone technologies and PIN numbers and the possible need for modest monetary incentives to keep patients sufficiently motivated to participate in the study.

## ADDITIONAL SUMMARY OF FINDINGS *[Explanation]*

Mobile phone text messages (comparing different intervals and lengths) for promoting adherence to antiretroviral therapy in patients with HIV infection						
Patient or population: Patients with HIV infection, on ART Settings: Kenya Intervention: Mobile phone text messages (comparing different intervals and lengths)						
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Mobile phone text messages (comparing different intervals and lengths)				
ART adherence at 48 weeks: Short weekly messages vs. long weekly messages	527 per 1000	516 per 1000 (369 to 733)	RR 0.98 (0.7 to 1.39)	147 (1 study)	⊕⊕○○ low <sup>1</sup>	
ART adherence at 48 weeks: Weekly vs. daily messages (overall)	408 per 1000	323 per 1000 (261 to 404)	RR 0.79 (0.64 to 0.99)	289 (1 study)	⊕⊕○○ low <sup>1</sup>	
ART adherence at 48 weeks: Short vs. long messages (overall)	473 per 1000	477 per 1000 (383 to 591)	RR 1.01 (0.81 to 1.25)	289 (1 study)	⊕⊕○○ low <sup>1</sup>	

\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  
CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

<sup>1</sup> Very few events.

## DISCUSSION

Difficulty in complying with ART regimens is an ongoing issue worldwide, and systematic reviews have addressed barriers and facilitators to doing so, as well as several key interventions (Mills 2006, Rueda 2006, Wise 2008, Bain-Brickley 2011, Barnighausen 2011, Saberi 2011). New interventions are urgently needed. Mobile phones and other new telecommunications technologies are being used to address a broad range of healthcare issues, from improving attendance in primary care (Leong 2006), to treating sexually transmitted infections (Menon-Johansson 2006), to supporting community-based peer health workers caring for people with HIV/AIDS (Chang 2011). An industry-funded narrative (non-systematic) review by Atun and colleagues provides an overview of these approaches (Atun 2006). A Cochrane review provides evidence that mobile phone text-messaging is efficacious in promoting adherence to tuberculosis medications (Liu 2008). A systematic review of electronic reminder devices (ERD) found significantly improved ART adherence in 4 of 8 studies examining ERD as a stand-alone intervention (Wise 2008). Another systematic review of technology-based self-care methods for improving adherence suggests that among the optimal characteristics of such tools were that like mobile phones, they should be easy to use and familiar to the patient, without attracting much attention (Saberi 2011). With adherence to ART such an important factor not only in improving individual patient health but also in reducing viral load sufficiently to prevent further HIV transmission (Anglemyer 2011), interventions such as mobile phone text-messaging have the potential to make a significant impact on the HIV epidemic. With the rapid expansion of mobile phone networks worldwide, particularly in regions that are new to these technologies (Guardian 2009, iTWire 2011), it will become more feasible to implement these interventions.

### Overall completeness and applicability of evidence

The two trials included in this review provide evidence of the efficacy of weekly text-messaging for enhancing adherence to ART in resource-constrained settings with generalised HIV epidemics. One trial provides evidence that weekly text-messaging may be efficacious in suppressing HIV viral load. Four small trials presently in the field, three of which are being conducted in resource-constrained settings, will strengthen the evidence base still further.

### Quality of the evidence

There is high-quality evidence from the two randomised controlled trials that mobile phone text-messaging at weekly intervals, whether the messages be short or long, is efficacious in enhancing adherence to ART. Although adherence in Lester 2010 was measured by self-report, we do not grade down for indirectness because the measured effect was consistent with that of weekly and short weekly messages in Pop-Eleches 2011 (as well as with the outcome measured biomedically in Lester 2010). There is high quality evidence from one trial that mobile phone text-messaging at weekly intervals is efficacious in improving HIV viral load suppression. There is low quality evidence from one trial that text-messaging at daily intervals is no more efficacious than standard care in promoting adherence to ART. The quality of evidence was graded down twice due to very few events.

## AUTHORS' CONCLUSIONS

### Implications for practice

Policy-makers should consider funding programs proposing to provide weekly mobile phone text-messaging as a means for promoting adherence to antiretroviral therapy. Clinics and hospitals should consider implementing such programs.

### Implications for research

There is a need for large RCTs of this intervention in adolescent populations, and in persons who care for children and infants with HIV. In contrast to the usual situation, there is a need for large RCTs of this intervention in high-income countries, as well as in middle-income countries. There is also a need for more evidence concerning the intervention's acceptability, and other qualitative concerns, including culture-specific data on message-content and message-length.

## ACKNOWLEDGEMENTS

We thank Dr. Andrew Anglemyer for reviewing our statistical analyses.

## REFERENCES

### References to studies included in this review

#### Lester 2010 *{published data only}*

Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. *Lancet* 2010 Nov 27;376(9755):1838–45.

#### Pop-Eleches 2011 *{published data only}*

Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP, de Walque D, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. *AIDS* 2011;25(6):825–34.

### References to studies excluded from this review

#### Ammassari 2011 *{published data only}*

Ammassari A, Trotta MP, Shalev N, Tettoni MC, Maschi S, Di Sora F, et al. Timed short messaging service improves adherence and virological outcomes in HIV-1-infected patients with suboptimal adherence to antiretroviral therapy. *Journal of acquired immune deficiency syndromes (1999)* 2011; Vol. 58, issue 4:e113–5. [PUBMED: 22033235]

#### Chi 2010 *{published data only}*

Chi BH, Stringer JS. Mobile phones to improve HIV treatment adherence. *Lancet* 2010 Nov 27;376(9755):1807–8.

#### De Costa 2010 *{published data only}*

De Costa A, Shet A, Kumarasamy N, Ashorn P, Eriksson B, Bogg L, et al. Design of a randomized trial to evaluate the influence of mobile phone reminders on adherence to first line antiretroviral treatment in South India—the HIVIND study protocol. *BMC medical research methodology* 2010;10:25. [PUBMED: 20346136]

#### Dowshen 2011 *{published data only}*

Dowshen N, Kuhns L, Johnson A, Holoyda B, Garofalo R. Text Message Reminders to Improve Adherence to Antiretroviral Therapy for HIV-Positive Youth. *Journal of Adolescent Health* Feb 2011; Vol. Volume 48, Issue 2, Supplement 1:S64–S65.

#### Haberer 2010 *{published data only}*

Haberer JE, Kiwanuka J, Nansera D, Wilson IB, Bangsberg DR. Challenges in using mobile phones for collection of antiretroviral therapy adherence data in a resource-limited setting. *AIDS and Behavior* 2010 Dec;14(6):1294–301.

#### Hardy 2011 *{published data only}*

Hardy H, Kumar V, Doros G, Farmer E, Drainoni ML, Rybin D, et al. Randomized controlled trial of a personalized cellular phone reminder system to enhance adherence to antiretroviral therapy. *AIDS Patient Care STDS* 2011 Mar; 25(3):153–61.

#### Kalichman 2011 *{published data only}*

Kalichman SC, Kalichman MO, Cherry C, Swetzes C, Amaral CM, White D, et al. Brief behavioral self-regulation

counseling for HIV treatment adherence delivered by cell phone: an initial test of concept trial. *AIDS Patient Care STDS* 2011 May;25(5):303–10.

#### Kelly 2011 *{published data only}*

Kelly JD, Giordano TP. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. *AIDS* 2011 May 15;25(8):1137; reply 8–9.

#### Mukund Bahadur 2010 *{published data only}*

Mukund Bahadur KC, Murray PJ. Cell phone short messaging service (SMS) for HIV/AIDS in South Africa: a literature review. *Stud Health Technol Inform* 210;160:Pt 1: 530–534.

#### Puccio 2006 *{published data only}*

Puccio JA, Belzer M, Olson J, Martinez M, Salata C, Tucker D, et al. The use of cell phone reminder calls for assisting HIV-infected adolescents and young adults to adhere to highly active antiretroviral therapy: a pilot study. *AIDS Patient Care STDS* 2006 Jun;20(6):438–44.

#### Reynolds 2008 *{published data only}*

Reynolds NR, Testa MA, Su M, Chesney MA, Neidig JL, Frank I, et al. Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial. *J Acquir Immune Defic Syndr* 2008 Jan 1;47(1):62–8.

#### Saberi 2011 *{published data only}*

Saberi P, Johnson MO. Technology-based self-care methods of improving antiretroviral adherence: a systematic review. *PloS one* 2011;6(11):e27533. [PUBMED: 22140446]

#### Safren 2003 *{published data only}*

Safren SA, Hendriksen ES, Desousa N, Boswell SL, Mayer KH. Use of an on-line pager system to increase adherence to antiretroviral medications. *AIDS Care* 2003 Dec;15(6):787–93.

#### Simoni 2007 *{published data only}*

Simoni JM, Pantalone DW, Plummer MD, Huang B. A randomized controlled trial of a peer support intervention targeting antiretroviral medication adherence and depressive symptomatology in HIV-positive men and women. *Health Psychol* 2007 Jul;26(4):488–95.

#### Skinner 2007 *{published data only}*

Skinner D, Rivette U, Bloomberg C. Evaluation of use of cellphones to aid compliance with drug therapy for HIV patients. *AIDS Care* 2007 May;19(5):605–7.

#### Wang 2008 *{published data only}*

Wang H, He G, Li X, Yang A, Chen X, Fennie KP, et al. Self-Reported adherence to antiretroviral treatment among HIV-infected people in Central China. *AIDS Patient Care STDS* 2008 Jan;22(1):71–80.

### References to studies awaiting assessment

#### da Costa 2012 *{published data only}*

da Costa TM, Barbosa BJ, E Costa DA, Sigulem D, de Fatima Marin H, Filho AC, et al. Results of a randomized

controlled trial to assess the effects of a mobile SMS-based intervention on treatment adherence in HIV/AIDS-infected Brazilian women and impressions and satisfaction with respect to incoming messages. *International journal of medical informatics* 2012 Jan 30;[Epub ahead of print]:n/a. [PUBMED: 22296762]

## References to ongoing studies

### Mbuagbaw 2011 *{published data only}*

Mbuagbaw L, Thabane L, Ongolo-Zogo P, Lester RT, Mills E, Volmink J, Yondo D, Essi MJ, Bonono-Momnougui RC, Mba R, Ndongo JS, Nkoa FC, Ondo HA. The Cameroon mobile phone SMS (CAMPS) trial: a protocol for a randomized controlled trial of mobile phone text messaging versus usual care for improving adherence to highly active anti-retroviral therapy. *Trials* 2011 Jan 7;12:5. PubMed PMID: 21211064;PubMed Central PMCID: PMC3023676.

### NCT01001741 *{published data only}*

A Pilot Study of Cellular Phone Text Message Reminders to Improve HIV Medication Adherence at Independence Surgery Clinic Gaborone, Botswana. Ongoing study 2008.

### NCT01049568 *{published data only}*

A Pilot Study Using Cell Phone Interactions to Improve Medication Adherence in Adolescents Who Have Previously Failed Antiretroviral Therapy Due to Non-Adherence. Ongoing study 2009.

### NCT01118767 *{published data only}*

Evaluation of a Computer-Based System Using Cell Phones for HIV People in Peru. Ongoing study 2010.

## Additional references

### Anglemyer 2011

Anglemyer A, Rutherford George W, Baggaley Rachel C, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. *Cochrane Database of Systematic Reviews* 2011, Issue 8. [DOI: 10.1002/14651858.CD009153.pub2; : CD009153]

### Atun 2006

Atun RA, Sittampalam S. A review of the characteristics and benefits of SMS in delivering healthcare. In: Atun RA, et al. editor(s). *The role of mobile phones in increasing accessibility and efficiency in healthcare*. Vodafone Group Plc, 2006.

### Bain-Brickley 2011

Bain-Brickley D, Butler Lisa M, Kennedy Gail E, Rutherford George W. Interventions to improve adherence to antiretroviral therapy in children with HIV infection. *Cochrane Database of Systematic Reviews* 2011, Issue 12. [DOI: 10.1002/14651858.CD009513; : CD009513]

### Barnighausen 2011

Barnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell ML. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. *The Lancet infectious diseases* 2011;11(12):942–51. [PUBMED: 22030332]

### Chang 2011

Chang LW, Kagaayi J, Arem H, Nakigozi G, Ssempijja V, Serwadda D, et al. Impact of a mHealth intervention for peer health workers on AIDS care in rural Uganda: a mixed methods evaluation of a cluster-randomized trial. *AIDS and behavior* 2011;15(8):1776–84. [PUBMED: 21739286]

### GRADEpro 2008

Brozek J, Oxman A, Schünemann. GRADEpro. GRADE Working Group, 2008.

### Guardian 2009

Wray R. *Africa sees massive growth in mobile web usage*. The Guardian, 2009. Available from: <http://www.guardian.co.uk/technology/2009/dec/22/mobilephones-internet>.

### Guyatt 2008

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ, GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; 336(7650):924–6.

### Higgins 2008

Higgins JPT, Green S (eds). *Cochrane Handbook for Systematic Reviews of Interventions*. Chichester: Wiley-Blackwell, 2008.

### iTWire 2011

Anonymous. Big three fuel Asia Pacific Mobile Growth. Available from: <http://www.itwire.com/it-industry-news/market/49228-big-three-fuel-asia-pacific-mobile-growth>.

### Leong 2006

Leong KC, Chen WS, Leong KW, Mastura I, Mimi O, Sheikh MA, Zailinawati AH, Ng CJ, Phua KL, Teng CL. The use of text messaging to improve attendance in primary care: a randomized controlled trial. *Fam Pract* 2006;23:699–705.

### Liu 2008

Liu Q, Abba K, Alejandria Marissa M, Balanag Vincent M, Berba Regina P, Lansang Mary Ann D. Reminder systems and late patient tracers in the diagnosis and management of tuberculosis. *Cochrane Database of Systematic Reviews* 2008, Issue 4. [DOI: 10.1002/14651858.CD006594.pub2; : CD006594]

### Menon-Johansson 2006

Menon-Johansson AS, McNaught F, Mandalia S, Sullivan AK. Texting decreases the time to treatment for genital Chlamydia trachomatis infection. *Sexually transmitted infections* 2006 Feb;82(1):49-51.

### Mills 2006

Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, Wilson K, Buchan I, Gill CJ, Cooper C. Adherence to HAART: A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators. *PLoS Med* 2006 Nov;3(11):e438.

### Palella 1998

Palella FJ, Delaney KM, Moorman AC, Loveless MO, et al. Declining morbidity and mortality among patients with

advanced human immunodeficiency virus infection. *N Engl J Med* 1998 Mar 26;**338**(13):853–60.

**RevMan 2011**

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan), Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.

**Rueda 2006**

Rueda S, Park-Wyllie Laura Y, Bayoumi A, Tynan A-M, Antoniou T, Rourke S, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. *Cochrane Database of Systematic Reviews* 2006, Issue 3. [DOI: 10.1002/14651858.CD001442.pub2; : CD001442]

**UNAIDS 2011**

Joint United Nations Programme on HIV/AIDS (UNAIDS), World Health Organization (WHO), United Nations Children's Fund (UNICEF). Global HIV/AIDS

Response: Epidemic update and health sector progress towards Universal Access. Geneva: UNAIDS, 2011.

**WHO 2009**

World Health Organization. Millennium Development Goal 6: Combat HIV/AIDS, malaria, and other diseases. Available from: <http://www.who.int/hiv/topics/mdg/info/en/>.

**WHO 2010**

World Health Organization. HIV drug resistance fact sheet. Available from: [http://www.who.int/hiv/facts/drug\\_resistance/en/index.html](http://www.who.int/hiv/facts/drug_resistance/en/index.html).

**Wise 2008**

Wise J, Operario D. Use of electronic reminder devices to improve adherence to antiretroviral therapy: a systematic review. *AIDS patient care and STDs* 2008;**22**(6):495–504. [PUBMED: 18462071]

\* Indicates the major publication for the study

## CHARACTERISTICS OF STUDIES

### Characteristics of included studies [ordered by study ID]

#### Lester 2010

Methods	Randomized controlled trial
Participants	538 HIV-infected adults initiating antiretroviral therapy (ART) in three clinics in Kenya
Interventions	Between May 2007-October 2008, 538 participants randomised to SMS (n=273) or to standard care (n=265). Messages were once weekly, were short: "How are you?" (in appropriate language), and requested response within 48 hours
Outcomes	<p>Primary outcomes were self-reported ART adherence (&gt;95% of prescribed doses in the past 30 days at both 6 and 12 month follow-up visits) and plasma HIV-1 viral RNA load suppression (&lt;400 copies per mL) at 12 months. The primary analysis was by intention to treat</p> <p><b>&gt;95% Adherence, 12 months</b></p> <ul style="list-style-type: none"> <li>• Mobile phone: 168/273</li> <li>• Standard care: 132/265</li> </ul> <p><b>Viral load suppression, 12 months</b></p> <ul style="list-style-type: none"> <li>• Mobile phone: 156/273</li> <li>• Standard care: 128/265</li> </ul> <p>The number needed to treat (NNT) to achieve greater than 95% adherence was nine (95% CI 5.0-29.5) and the NNT to achieve viral load suppression was 11 (5.8-227.3)</p>
Notes	

#### *Risk of bias*

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	A project statistician generated the randomisation code with a random number generating program
Allocation concealment (selection bias)	Low risk	Written allocation of assignment was sealed in individual opaque envelopes marked with study identification numbers, which were distributed to all three study clinics
Blinding of participants and personnel (performance bias) All outcomes	Low risk	No blinding, but outcome and outcome measurement unlikely to be influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Randomisation, laboratory assays, and analyses were done by investigators masked to treatment allocation
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patients and outcomes were accounted for.

Lester 2010 (Continued)

Selective reporting (reporting bias)	Low risk	No evidence of selective reporting. This trial is registered with ClinicalTrials.gov, NCT00830622
Other bias	Low risk	

Pop-Eleches 2011

Methods	Randomized controlled trial	
Participants	Four hundred and thirty-one adult patients who had initiated ART within 3 months at a rural clinic in Kenya. Seven hundred and thirty-five patients were approached and 720 (97.9%) were enrolled. Analyses are restricted to 431 participants enrolled before 31 January 2008	
Interventions	Participants were randomly assigned to one of four intervention groups or to the control group that would receive no text messages. One-third of the sample was allocated to the control group, and the remaining two-thirds of the sample were allocated evenly to each of the four intervention groups. The text messages were provided in English, Dhoulou or Kiswahili (as appropriate). The content of the short message was "This is your reminder. The content of the long message was "This is your reminder. Be strong and courageous. We care about you."	
Outcomes	<p>The primary outcome was whether adherence exceeded 90% during each 12-week period of analysis and the 48-week study period. Outcomes are broken out by which patients got the short daily, short weekly, long daily, long weekly messages. Overall (all lengths, all timing) data are also provided</p> <p><b>Adherence &gt;90% at 48 weeks:</b>          (Number of events per arm is back-calculated from proportional figures provided by the authors. These proportional figures are given below in parentheses.)</p> <ul style="list-style-type: none"> <li>• Any text messages: 136/289 (0.47)</li> <li>• Short weekly messages: 39/73 (0.53)</li> <li>• Long weekly messages: 39/74 (0.53)</li> <li>• Short daily: 28/70 (0.40)</li> <li>• Long daily: 30/72 (0.42)</li> <li>• Standard care: 56/139 (0.40)</li> </ul>	
Notes		

*Risk of bias*

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The randomisation schedule was prepared in advance of enrollment by the investigators. A sequence of random numbers between 0 and 1 was generated, and four equal intervals between 0 and 1 corresponded to the four intervention groups, whereas the value interval from 2/3 to 1 corresponded to the control group

**Pop-Eleches 2011** (Continued)

Allocation concealment (selection bias)	Unclear risk	One-third of the sample was allocated to the control group, and the remaining two-thirds of the sample was allocated evenly to each of the four intervention groups. Further detail was not provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	No blinding, but outcome and outcome measurement unlikely to be influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Unclear, but outcome and outcome measurement unlikely to be influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patients and outcomes were accounted for.
Selective reporting (reporting bias)	Unclear risk	No evidence of selective reporting. The trial is registered at ClinicalTrials.gov (NCT01058694)
Other bias	Low risk	

**Characteristics of excluded studies** [ordered by study ID]

Study	Reason for exclusion
Ammassari 2011	Not an RCT
Chi 2010	Letter in regard to <a href="#">Lester 2010</a>
De Costa 2010	Protocol for an RCT. The trial will include voice messages and picture messages
Dowshen 2011	Not an RCT
Haberer 2010	Additional data for <a href="#">Pop-Eleches 2011</a>
Hardy 2011	Control was another experimental intervention ("Beeper")
Kalichman 2011	Not text messaging
Kelly 2011	Letter in regard to <a href="#">Pop-Eleches 2011</a>
Mukund Bahadur 2010	Systematic review, but no RCTs of text-messaging for adherence
Puccio 2006	Not an RCT

(Continued)

Reynolds 2008	Not text messaging
Saberi 2011	Systematic review, but no RCTs of text-messaging for adherence
Safren 2003	Not mobile phones, not an RCT
Simoni 2007	Not text messaging
Skinner 2007	Not text messaging
Wang 2008	Not text messaging

### Characteristics of studies awaiting assessment [ordered by study ID]

#### da Costa 2012

Methods	Randomised controlled trial
Participants	HIV+ women in Brazil (n=21)
Interventions	"Participants in the intervention group (n=8) received SMS messages 30min before their last scheduled time for a dose of medicine during the day. The messages were sent every Saturday and Sunday and on alternate days during the working week. Participants in the control group (n=13) did not receive messages."
Outcomes	Self-reported adherence; qualitative outcomes.
Notes	This newly-published study (30 Jan 2012) was identified after this review was finalised and just before it went to press. Will consider for inclusion in an update of this review, later in 2012

### Characteristics of ongoing studies [ordered by study ID]

#### Mbuagbaw 2011

Trial name or title	The Cameroon mobile phone SMS (CAMPS) trial: A randomized controlled trial of mobile phone text messaging versus usual care for improving adherence to highly active anti-retroviral therapy
Methods	Single-centered randomized controlled single-blinded trial
Participants	Subjects who are aged above 21 years, own a mobile phone and can read text messages, and who have been on HAART for at least a month. N=198
Interventions	A short weekly text message to the participants in the intervention group in both French and English. The content of the message will be motivating and will act both as a reminder and a cue to action. The message will also contain a phone number they can call back if they need help

**Mbuagbaw 2011** (Continued)

Outcomes	Adherence. Secondary endpoints will be; <ul style="list-style-type: none"> <li>• Clinical: Weight, BMI, opportunistic infections</li> <li>• Biological: CD4 count, viral load</li> <li>• Quality of life (QOL): Measured with the SF-12 QOL assessment form</li> <li>• All cause mortality</li> <li>• Retention</li> </ul>
Starting date	2010
Contact information	Lawrence Mbuagbaw: mbuagbaw1@yahoo.com
Notes	<a href="http://clinicaltrials.gov/NCT01247181">http://clinicaltrials.gov/NCT01247181</a>

**NCT01001741**

Trial name or title	A Pilot Study of Cellular Phone Text Message Reminders to Improve HIV Medication Adherence at Independence Surgery Clinic Gaborone, Botswana
Methods	Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Participants	Inclusion Criteria: - HIV infected - 21 years of age or older Exclusion Criteria: - Subjects who do not intend to have continuous follow-up care and monthly medication refills at Independence Surgery for at least the next six months. N=40
Interventions	Unclear
Outcomes	HIV medication adherence [Time Frame: Monthly]
Starting date	2008
Contact information	Nikki Jones, University of Pennsylvania
Notes	<a href="http://apps.who.int/trialsearch/Trial.aspx?TrialID=NCT01001741">http://apps.who.int/trialsearch/Trial.aspx?TrialID=NCT01001741</a>

**NCT01049568**

Trial name or title	A Pilot Study Using Cell Phone Interactions to Improve Medication Adherence in Adolescents Who Have Previously Failed Antiretroviral Therapy Due to Non-Adherence
Methods	Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Participants	Inclusion Criteria: Documented HIV-positive (age 15-24) infected either behaviorally or perinatally as determined by medical record review or verbal verification from referring professional. Age 15 and 0 days to 24 years and 364 days. Enrolled in care at an AMTU or affiliated site. History of non-adherence to one

**NCT01049568** (Continued)

	or more components of antiretroviral therapy, defined as meeting one of the following criteria: - Currently prescribed HAART and reports to care provider less than 90% adherence in previous month and has viral load greater than 1000 copies/ml when last evaluated (within the last four weeks); - Discontinued HAART in the past while documented to be less than 90% adherent during the most recent antiretroviral treatment; and - Agreed to initiate antiretroviral treatment in the past, but never initiated. Able to speak and understand English. Willing to provide informed consent or assent. Exclusion Criteria: Evidence of cognitive impairment or other mental condition (including substance abuse) that limits his/her ability to complete intervention and assessments (per PI or designee discretion). Participants with stable and treated mental health/substance abuse disorders are acceptable for inclusion with protocol team approval. Any condition, including active substance abuse that is expected to limit the likelihood that the participant may maintain involvement for the entire year on-study (per PI or designee discretion with protocol team approval). No participant consent, parental permission or youth assent (as appropriate). Minors unable to acquire parental/guardian consent, even if not living at home, will not be able to participate as a change in housing status during the study might require premature discontinuation. Current participation in another behavioral interventional trial. N=40, USA
Interventions	Unclear
Outcomes	To examine the content of the Adherence Facilitator's conversation; including reported stressful life circumstances, what solutions were offered, and acceptability of the intervention among intervention participants [Time Frame: 1 year] To examine the trends of therapeutic success at 6 and 12 months, as measured by lowered viral load, and self-reported adherence among intervention versus control group participants [Time Frame: 1 year]
Starting date	2009
Contact information	Not provided
Notes	<a href="http://apps.who.int/trialsearch/Trial.aspx?TrialID=NCT01049568">http://apps.who.int/trialsearch/Trial.aspx?TrialID=NCT01049568</a>

**NCT01118767**

Trial name or title	Evaluation of a Computer-Based System Using Cell Phones for HIV People in Peru
Methods	RCT
Participants	Inclusion Criteria: HIV-positive healthy male or female aged greater than or equal to 18 - Currently on ART - Patients with a mobile phone for their personal use (not shared) - Patients who know how to retrieve read text messages on their mobile phone - Signed and dated written informed consent prior to admission to the study Exclusion Criteria: - Patients whose clinical condition might have interfered with the study (e.g., deafness, serious mental illness, mental retardation) - Patients unable to give their informed consent. N=200
Interventions	Unclear
Outcomes	HIV-1 viral load, Self-reported medication adherence [Time Frame: 12 months]
Starting date	2010

**NCT01118767** (Continued)

Contact information	Walter H Curioso, MD, MPH, walter.curioso@upch.pe
Notes	<a href="http://apps.who.int/trialsearch/Trial.aspx?TrialID=NCT01001741">http://apps.who.int/trialsearch/Trial.aspx?TrialID=NCT01001741</a>

## DATA AND ANALYSES

### Comparison 1. Mobile phone text messages vs. standard care

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Viral load suppression at 52 weeks	1	538	Risk Ratio (M-H, Fixed, 95% CI)	0.83 [0.69, 0.99]
2 ART adherence at 48-52 weeks: Text messages vs. standard care (overall)	2	966	Risk Ratio (M-H, Fixed, 95% CI)	0.82 [0.72, 0.94]
3 ART adherence at 48-52 weeks: Weekly text messages vs. standard care (overall)	2	898	Risk Ratio (M-H, Fixed, 95% CI)	0.78 [0.68, 0.89]
4 ART adherence at 48-52 weeks: Short weekly messages vs. standard care	2	750	Risk Ratio (M-H, Fixed, 95% CI)	0.77 [0.66, 0.90]
5 ART adherence at 48 weeks: Long weekly messages vs. standard care	1	213	Risk Ratio (M-H, Fixed, 95% CI)	0.79 [0.60, 1.04]
6 ART adherence at 48 weeks: Daily messages vs. standard care (overall)	1	281	Risk Ratio (M-H, Fixed, 95% CI)	0.99 [0.82, 1.20]
7 ART adherence at 48 weeks: Short daily messages vs. standard care	1	209	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.79, 1.27]
8 ART adherence at 48 weeks: Long daily messages vs. standard care	1	211	Risk Ratio (M-H, Fixed, 95% CI)	0.98 [0.77, 1.24]

### Comparison 2. Mobile phone text messages (comparing different intervals and lengths)


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 ART adherence at 48 weeks: Short weekly messages vs. long weekly messages	1	147	Risk Ratio (M-H, Fixed, 95% CI)	0.98 [0.70, 1.39]
2 ART adherence at 48 weeks: Weekly vs. daily messages (overall)	1	289	Risk Ratio (M-H, Fixed, 95% CI)	0.79 [0.64, 0.99]
3 ART adherence at 48 weeks: Short vs. long messages (overall)	1	289	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.81, 1.25]

### Analysis 1.1. Comparison 1 Mobile phone text messages vs. standard care, Outcome 1 Viral load suppression at 52 weeks.

Review: Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection

Comparison: 1 Mobile phone text messages vs. standard care

Outcome: 1 Viral load suppression at 52 weeks




### Analysis 1.2. Comparison 1 Mobile phone text messages vs. standard care, Outcome 2 ART adherence at 48-52 weeks: Text messages vs. standard care (overall).

Review: Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection

Comparison: 1 Mobile phone text messages vs. standard care

Outcome: 2 ART adherence at 48-52 weeks: Text messages vs. standard care (overall)




### Analysis I.3. Comparison I Mobile phone text messages vs. standard care, Outcome 3 ART adherence at 48-52 weeks: Weekly text messages vs. standard care (overall).

Review: Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection

Comparison: I Mobile phone text messages vs. standard care

Outcome: 3 ART adherence at 48-52 weeks: Weekly text messages vs. standard care (overall)




### Analysis I.4. Comparison I Mobile phone text messages vs. standard care, Outcome 4 ART adherence at 48-52 weeks: Short weekly messages vs. standard care.

Review: Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection

Comparison: I Mobile phone text messages vs. standard care

Outcome: 4 ART adherence at 48-52 weeks: Short weekly messages vs. standard care




**Analysis I.5. Comparison I Mobile phone text messages vs. standard care, Outcome 5 ART adherence at 48 weeks: Long weekly messages vs. standard care.**

Review: Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection

Comparison: I Mobile phone text messages vs. standard care

Outcome: 5 ART adherence at 48 weeks: Long weekly messages vs. standard care




**Analysis I.6. Comparison I Mobile phone text messages vs. standard care, Outcome 6 ART adherence at 48 weeks: Daily messages vs. standard care (overall).**

Review: Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection

Comparison: I Mobile phone text messages vs. standard care

Outcome: 6 ART adherence at 48 weeks: Daily messages vs. standard care (overall)




**Analysis 1.7. Comparison 1 Mobile phone text messages vs. standard care, Outcome 7 ART adherence at 48 weeks: Short daily messages vs. standard care.**

Review: Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection

Comparison: 1 Mobile phone text messages vs. standard care

Outcome: 7 ART adherence at 48 weeks: Short daily messages vs. standard care




### Analysis 1.8. Comparison 1 Mobile phone text messages vs. standard care, Outcome 8 ART adherence at 48 weeks: Long daily messages vs. standard care.

Review: Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection

Comparison: 1 Mobile phone text messages vs. standard care

Outcome: 8 ART adherence at 48 weeks: Long daily messages vs. standard care




### Analysis 2.1. Comparison 2 Mobile phone text messages (comparing different intervals and lengths), Outcome 1 ART adherence at 48 weeks: Short weekly messages vs. long weekly messages.

Review: Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection

Comparison: 2 Mobile phone text messages (comparing different intervals and lengths)

Outcome: 1 ART adherence at 48 weeks: Short weekly messages vs. long weekly messages




### Analysis 2.2. Comparison 2 Mobile phone text messages (comparing different intervals and lengths), Outcome 2 ART adherence at 48 weeks: Weekly vs. daily messages (overall).

Review: Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection

Comparison: 2 Mobile phone text messages (comparing different intervals and lengths)

Outcome: 2 ART adherence at 48 weeks: Weekly vs. daily messages (overall)




### Analysis 2.3. Comparison 2 Mobile phone text messages (comparing different intervals and lengths), Outcome 3 ART adherence at 48 weeks: Short vs. long messages (overall).

Review: Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection

Comparison: 2 Mobile phone text messages (comparing different intervals and lengths)

Outcome: 3 ART adherence at 48 weeks: Short vs. long messages (overall)



## ADDITIONAL TABLES

Table 1. Effects of the interventions

Study	Intervention vs. standard care	Outcome	Measured	Effect (non-event)
Lester 2010	Short weekly messages	Viral load suppression	52 weeks	RR 0.83, 95% CI 0.69 to 0.99
Lester 2010	Short weekly messages	>95% adherence	52 weeks	RR 0.77, 95% CI 0.63 to 0.93
Pop-Eleches 2011	Short weekly messages	>90% adherence	48 weeks	RR 0.78, 95% CI 0.59 to 1.03
Pop-Eleches 2011	Long weekly messages	>90% adherence	48 weeks	RR 0.79, 95% CI 0.60 to 1.04
Pop-Eleches 2011	Short daily messages	>90% adherence	48 weeks	RR 1.00, 95% CI 0.79 to 1.27
Pop-Eleches 2011	Long daily messages	>90% adherence	48 weeks	RR 0.98, 95% CI 0.77 to 1.24
Pop-Eleches 2011	Any text messages	>90% adherence	48 weeks	RR 0.89, 95% CI 0.74 to 1.06

## APPENDICES

### Appendix I. PubMed search strategy, modified as appropriate for use in the other databases

Search	PubMed
#4	Search ((#1) AND #2) AND #3
#3	Search (HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tiab] OR hiv-1[tiab] OR hiv-2*[tab] OR hiv1[tiab] OR hiv2[tiab] OR hiv infect*[tiab] OR human immunodeficiency virus[tiab] OR human immune deficiency virus[tiab] OR human immuno-deficiency virus[tiab] OR human immune-deficiency virus[tiab] OR ((human immun*) AND (deficiency virus[tiab])) OR acquired immunodeficiency syndromes[tiab] OR acquired immune deficiency syndrome[ tiab] OR acquired immuno-deficiency syndrome[ tiab] OR acquired immune-deficiency syndrome[ tiab] OR ((acquired immun*) AND (deficiency syndrome[tiab])) OR “sexually transmitted diseases, viral”[mh]) OR HIV[tiab] OR HIV/AIDS[tiab] OR HIV-infected[tiab] OR HIV[title] OR HIV/AIDS[title] OR HIV-infected[title])
#2	Search (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized controlled trials[mh] OR random allocation[mh] OR double-blind method[mh] OR single-blind method[mh] OR clinical trial[pt] OR trial[tw] OR clinical trials[mh] OR (“clinical trial”[tw]) OR ((singl*[tw] OR doubl*[tw] OR trebl*[tw] OR tripl*[tw]) AND (mask*[tw] OR blind*[tw])) OR placebos[mh] OR placebo*[tw] OR random*[tw] OR non-randomi*[tw] OR research design [mh:noexp] OR follow-up studies[ mh] OR prospective studies[mh] OR control*[tw] OR prospectiv*[tw] OR volunteer*[tw] OR longitud*[tw] OR descripti*[tiab] OR study[tiab] OR evaluat*[ tiab])

(Continued)

#1	Search ("Medication Adherence"[Mesh] AND "Cellular Phone"[Mesh]) OR ((adherence[ti] OR compliance[ti]) AND (telephone[tiab] OR mobile[tiab] OR cellphone[tiab] OR "cell phone"[tiab] OR sms[tiab] OR text*[ti]))
----	--

## WHAT'S NEW

Last assessed as up-to-date: 8 February 2012.

Date	Event	Description
7 March 2012	Amended	Added something to "Implications for research."

## HISTORY

Review first published: Issue 3, 2012

## CONTRIBUTIONS OF AUTHORS

TH and HA screened references and extracted data. TH also wrote the protocol, designed the data abstraction form, performed the searches, led the analyses, and wrote the review. GEK and GWR contributed significantly to the analysis and interpretation of the review's findings.

## DECLARATIONS OF INTEREST

No known conflicts of interest.

## SOURCES OF SUPPORT

### Internal sources

- UCSF Global Health Sciences, at University of California, San Francisco, USA.

## External sources

- No sources of support supplied

## DIFFERENCES BETWEEN PROTOCOL AND REVIEW

None.

## NOTES

We anticipate preparing an update of this review in late 2012.

## INDEX TERMS

### Medical Subject Headings (MeSH)

\*Cellular Phone; \*HIV-1; \*Medication Adherence; \*Text Messaging; Anti-HIV Agents [\*therapeutic use]; HIV Infections [\*drug therapy]; Health Promotion [methods]; Kenya; Randomized Controlled Trials as Topic; Time Factors

### MeSH check words

Adult; Humans